Carrie Cox Net Worth
The estimated Net Worth of Carrie Smith Cox is at least $2.79 Million dollars as of 6 June 2019. Ms. Cox owns over 10,000 units of Celgene stock worth over $2,261,490 and over the last 15 years she sold CELG stock worth over $0. In addition, she makes $525,470 as Independent Director at Celgene.
Ms. Cox CELG stock SEC Form 4 insider trading
Carrie has made over 30 trades of the Celgene stock since 2004, according to the Form 4 filled with the SEC. Most recently she bought 10,000 units of CELG stock worth $18,200 on 6 June 2019.
The largest trade she’s ever made was exercising 24,900 units of Celgene stock on 25 October 2013 worth over $1,311,483. On average, Carrie trades about 2,009 units every 58 days since 2004. As of 6 June 2019 she still owns at least 21,000 units of Celgene stock.
You can see the complete history of Ms. Cox stock trades at the bottom of the page.
Carrie Cox biography
Carrie S. Cox is Independent Director of Celgene Corp. Ms. Cox currently serves as the Chairman of the Board of Directors and Chief Executive Officer of Humacyte, Inc., a privately-held regenerative medicine company primarily focused on developing novel human tissue-based investigational products for applications in regenerative medicine and vascular surgery. Ms. Cox served as Executive Vice President of Schering-Plough and President of Schering-Plough’s Global Pharmaceutical Business until November 3, 2009 when Schering-Plough merged with Merck & Co., Inc. Prior to joining Schering-Plough, Ms. Cox served as President of Pharmacia Corporation’s pharmaceutical business until its merger with Pfizer Inc. in 2003. Ms. Cox is a member of the Board of Directors of Texas Instruments and has served on their Audit and Compensation Committees, and is a member of the Board of Directors of Cardinal Health, Inc. and sits on its Compensation Committee. Ms. Cox is a graduate of the Massachusetts College of Pharmacy. Ms. Cox brings to her service as a director her distinguished career in global healthcare and her significant experience and leadership serving in executive positions of some of the largest and most successful multi-national healthcare companies in the world, including with responsibility for those companies’ financial performance and significant capital and research and development investments.
What is the salary of Carrie Cox?
As the Independent Director of Celgene, the total compensation of Carrie Cox at Celgene is $525,470. There are 6 executives at Celgene getting paid more, with Mark Alles having the highest compensation of $13,116,000.
How old is Carrie Cox?
Carrie Cox is 61, she’s been the Independent Director of Celgene since 2009. There are 9 older and 6 younger executives at Celgene. The oldest executive at Celgene Corp. is Ernest Mario, 80, who is the Independent Director.
What’s Carrie Cox’s mailing address?
Carrie’s mailing address filed with the SEC is C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER, CO, 80301.
Insider trading at Celgene
Over the last 16 years, insiders at Celgene have traded over $348,919,594 worth of Celgene stock and bought 171,908 units worth $10,354,899 . The most active insider traders include Sol J Barer, Robert J Hugin, and John W Jackson. On average, Celgene executives and independent directors trade stock every 13 days with the average trade being worth of $5,423,484. The most recent stock trade was executed by Jonathan Biller on 31 October 2019, trading 3,125 units of CELG stock currently worth $336,531.
What does Celgene do?
Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include REVLIMID, POMALYST, IMNOVID, OTEZLA, ABRAXANE, and VIDAZA. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.
What does Celgene’s logo look like?
Complete history of Ms. Cox stock trades at Celgene, Texas Instruments, Cardinal Health, and electroCore
Celgene executives and stock owners
Celgene executives and other stock owners filed with the SEC include:
- Mark Alles, Chairman of the Board, Chief Executive Officer
- Peter Kellogg, Executive Vice President and Chief Corporate Strategy Officer
- Rupert Vessey, President – Research and Early Development
- Michael Casey, Lead Independent Director
- James Loughlin, Independent Director
- Ernest Mario, Independent Director
- Julia Haller, Director
- Carrie Cox, Independent Director
- Michael Bonney, Independent Director
- Richard Barker, Independent Director
- Michael Friedman, Independent Director
- John Weiland, Independent Director
- Patricia Hemingway Hall, Independent Director
- Hans Bishop, Director
- Jonathan Biller, Executive Vice President, General Counsel
- Alise Reicin, President – Global Clinical Development
- Terrie Curran, President, Global Inflammation & Immunology Franchise
- David Elkins, Chief Financial Officer, Executive Vice President
- Michael F. Pehl, See remarks
- Gerald Masoudi, Executive Vice President
- Gilla Phd Kaplan, Director
- Scott Andrew Smith, See Remarks
- Robert J Hugin, Chief Financial Officer
- Nadim Ahmed, PRES., HEMATOLOGY AND ONCOLOGY
- Lawrence V Stein, See Remarks
- Rodman L Drake, Chief Operating Officer
- Thomas O Daniel, see remarks
- Hoek Andre Van, Controller and CAO
- Walter L Robb, Director
- Graham Burton, See Remarks
- David W Gryska, Chief Financial Officer
- Aart Brouwer, See Remarks
- Sol J Barer, Chief Operating Officer
- Richard C E Morgan, Director
- Arthur H Jr Hayes, Director
- Thomas M Moriarty, see remarks
- Jacqualyn A Fouse, Chief Financial Officer
- Perry A Karsen, see remarks
- Jack L Bowman, Director
- Frank T Cary, Director
- John W Jackson, Chief Executive Officer